<DOC>
	<DOCNO>NCT02211417</DOCNO>
	<brief_summary>This study compare safety efficacy DS107G ( 2 g ) placebo patient moderate severe atopic dermatitis . DS107G capsule ( 2 g ) orally administer 8 week , compare placebo . This study enroll approximately 100 adult patient .</brief_summary>
	<brief_title>Oral DS107G Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description>Subjects come clinic 6 occasion : screening , baseline , week 2 , week 4 , week 8 ( end treatment/early termination ) week 10 ( follow-up ) . The primary efficacy variable IGA . Secondary efficacy variable include IGA ( Investigator 's Global Assessment ) , SCORAD ( Scoring Atopic Dermatitis ) visual analog scale ( VAS ) ) , EASI , BSA ( Body Surface Area ) , POEM ( Patient Orientated Eczema Measure ) , DLQI ( Dermatology Life Quality Index ) , SCORAD .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject age 18 year old . Moderate severe atopic dermatitis . Clinically significant impairment renal hepatic function . History hypersensitivity substance DS107G placebo capsule . Treatment experimental drug within 30 day prior Day 0 visit ( baseline ) . Excessive sun exposure , use tan booth ultraviolet ( UV ) light source and/or plan trip sunny climate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>